Alumis Inc./$ALMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Ticker
$ALMS
Sector
Primary listing
Employees
226
Headquarters
Website
Alumis Inc. Metrics
BasicAdvanced
$2.8bn
-
-$2.31
-
-
Price and volume
Market cap
$2.8bn
52-week high
$30.60
52-week low
$2.76
Average daily volume
1.1m
Financial strength
Current ratio
7.509
Quick ratio
7.414
Long term debt to equity
5.506
Total debt to equity
6.29
Profitability
EBITDA (TTM)
-435.261
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,825.70%
Operating margin (TTM)
-5,222.39%
Effective tax rate (TTM)
3.48%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-58.79%
Return on equity (TTM)
-64.57%
Valuation
Price to revenue (TTM)
272.884
Price to book
5.01
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
-6.081
Free cash flow yield (TTM)
-16.44%
Free cash flow per share (TTM)
-3.67
Growth
Revenue change (TTM)
-51.68%
Earnings per share change (TTM)
-72.19%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs